Home Cart Sign in  
Chemical Structure| 951382-34-6 Chemical Structure| 951382-34-6

Structure of Ipragliflozin (L-Proline)
CAS No.: 951382-34-6

Chemical Structure| 951382-34-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ipragliflozin (L-Proline) selectively inhibits SGLT2 with IC50 of 2.8 nM.

Synonyms: Ipragliflozin L-Proline

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ipragliflozin (L-Proline)

CAS No. :951382-34-6
Formula : C26H30FNO7S
M.W : 519.58
SMILES Code : O=C([C@H]1NCCC1)O.O[C@H]2[C@H](C3=CC=C(F)C(CC4=CC5=CC=CC=C5S4)=C3)O[C@H](CO)[C@@H](O)[C@@H]2O
Synonyms :
Ipragliflozin L-Proline
MDL No. :MFCD27956926
InChI Key :TUVGWWULBZIUBS-FVYIYGEMSA-N
Pubchem ID :57339444

Safety of Ipragliflozin (L-Proline)

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C2C12 cells 10 μM Ipragliflozin enhanced C2C12 cell viability under hyperglycemic conditions, inhibited ferroptosis, and restored GPX4 expression. PMC10203292

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Western diet-induced obese and diabetic mouse model Oral administration via drinking water 10 mg/kg Daily administration for 10 weeks To evaluate the effect of Ipragliflozin on vascular remodeling. Results showed that Ipra increased adipocyte size in abdominal PVAT, reduced inflammation and fibrosis, and inhibited vascular remodeling. PMC6589884
129S6/Sv mice High-fat diet-induced obesity model Oral gavage 10 mg/kg Once daily for 16 weeks To investigate the effect of ipragliflozin on energy metabolism in high-fat diet-induced obese mice. Results showed that ipragliflozin significantly attenuated HFD-induced hepatic steatosis, reduced adipocyte size, and upregulated thermogenesis-related gene expression in visceral and subcutaneous adipose tissue. PMC8640151
FLS-ob/ob mice Non-alcoholic steatohepatitis (NASH) model Oral gavage 1 mg/kg Once daily for 12 weeks Ipragliflozin improved lipid metabolism in FLS-ob/ob mice, reduced ectopic lipid deposition (ELD) in renal tubules, decreased endoplasmic reticulum stress (ER stress) and apoptosis, and attenuated interstitial fibrosis. PMC6981520
Mice High-fat diet (HFD)-induced diabetic nephropathy model Oral (via drinking water) 10 mg/kg Once daily for 6 weeks To investigate the effect of Ipra on HFD-induced diabetic nephropathy, results showed that Ipra reduced urinary albumin excretion (UAE) and glomerular hypertrophy, while increasing adipocyte size in PRAT and suppressing inflammation and fibrosis. PMC8304702
C57BL/6JJcl mice Streptozotocin (STZ)-induced diabetic mouse model Oral 0.1 mg/kg or 3 mg/kg Once daily for 4 weeks To evaluate the protective effect of SGLT2 inhibitors on early pathogenic alterations in diabetic retinopathy. Results showed that ipragliflozin at a low dose (0.1 mg/kg/day) significantly suppressed retinal vascular leakage and retinal thickness without affecting blood glucose levels. Additionally, ipragliflozin attenuated microglial morphological changes and early pathogenic alterations. PMC11208076
Mice DIO mice Oral 0.002% in the diet 4 weeks To evaluate the effects of ipragliflozin alone or in combination with liraglutide on glycemic control and hepatic lipid accumulation in DIO mice. Results showed that ipragliflozin improved glycemic control and reduced hepatic lipid accumulation. PMC8583813
Mice Db/db mice Oral 0.001% in the diet 4 weeks To evaluate the effects of ipragliflozin alone or in combination with liraglutide on glycemic control and hepatic lipid accumulation in db/db mice. Results showed that ipragliflozin improved glycemic control and reduced hepatic lipid accumulation. PMC8583813
Mice Type 2 diabetes model Oral gavage 3 mg/kg/day and 0.3 mg/kg/day Once daily for 8 weeks To investigate the renoprotective effects of ipragliflozin on early diabetic nephropathy. High-dose ipragliflozin lowered blood glucose levels and reduced urinary albumin excretion, inhibited renal and glomerular hypertrophy, and reduced NADPH oxidase 4 expression and oxidative stress. A short-term ipragliflozin treatment improved oxygen tension in the kidney cortex. PMC5838225
Rats Normal and type 2 diabetic Goto–Kakizaki (GK) rats Ad libitum feeding 0.008% (w/w) mixed into diet Daily for 20 days To investigate the time-dependent effects of ipragliflozin on behaviour and energy homeostasis, results showed ipragliflozin increased food and water intakes, decreased blood glucose, and enhanced basal energy expenditure. PMC5605532

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.92mL

0.38mL

0.19mL

9.62mL

1.92mL

0.96mL

19.25mL

3.85mL

1.92mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories